Join Growin Stock Community!
Back to NVO.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

cash-and-debt-chart

NVO Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q4'25, Novo Nordisk (NVO) reported Cash & Short-term Investments of USD 26.96B and Debt of USD 130.96B. This marks a significant gap between cash reserves and debt levels at the latest data point, with debt reaching its highest value in the period covered. From Q1'23 to Q4'25, the chart reveals considerable volatility in both cash and debt positions. Cash & Short-term Investments peaked at USD 74.88B in Q3'24 before declining sharply, while debt saw a substantial increase starting in Q2'24, accelerating from USD 27.06B in Q4'23 to USD 130.96B by Q4'25. The overall trend indicates rising leverage, with debt growth far outpacing cash accumulation, especially from 2024 onwards.